The Food and Drug Safety Center (FDSC) provides safety testing of pharmaceuticals, medical devices, health foods, and other related products.
This page provides detailed information about FDSC’s non-clinical studies, examples of disease models, and case studies.
We hope it serve as a useful reference when selecting a contract organization for your needs.
FDSC provides high-quality safety testing in compliance with various guidelines.
In addition to the Ministry of Health, Labour and Welfare (MHLW) guidelines, they perform evaluations according to the recommendations by international standards such as ISO 10993, FDA, ASTM, and OECD.
Since 1970, FDSC has been engaged in a wide range of safety evaluations related to food, pharmaceuticals, and medical devices.
As of October 2024, the Center had conducted over 70,000 tests in total.
They have worked with numerous manufacturers for their biological safety testing of medical devices.
Beyond providing test results, FDSC offers comprehensive follow-up services, including consultations regarding inquiries from regulatory authorities based on study outcomes.
FDSC supports a broad spectrum of safety tests, including cytotoxicity, skin sensitization, local irritation, systemic toxicity, genotoxicity, pathological examinations, implantation, blood compatibility, extraction efficiency, and quality control tests and more.
Since 1980, they have provided many GLP compliant studies and can also perform quality control testing in accordance with GMP standards.
No information regarding partnered organizations was found on the official website.
Extracts of pharmaceuticals, chemicals, or medical materials are administered once to animals (e.g., mice or rats) orally, intravenously, or dermally, to observe potential toxic effect.
Evaluation items include general condition, body weight change, and pathological examination.
This study aims to evaluate toxicological changes in animals administered daily or implanted with medical devices over periods ranging from two weeks to one year.
Mice, rats, and rabbits are used as test species, with evaluations including general condition, body weight change, food and water intake, urinalysis, hematology, ophthalmology, and pathological examination.
The Food and Drug Safety Center conducts tests in accordance with international standards such as ISO 10993, FDA, ASTM, and OECD, as well as the guidelines of Japan’s Ministry of Health, Labour and Welfare (MHLW).
| Address | 729-5 Ochiai, Hadano City, Kanagawa Prefecture, Japan |
|---|---|
| Tel | 0463-82-4751 |
| Website | https://www.fdsc.or.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.